Business Description
Protalix BioTherapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US74365A3095
Total Employee Number:
226Compare
Compare
Traded in other countries / regions
PLX.USAPBDA.Germany Index Membership
Russell 2000Russell 3000Russell 2000Russell 3000 IPO Date
1996-01-02Description
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.02 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | 0.38 | |||||
Interest Coverage | 12.86 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 0.36 | |||||
Beneish M-Score | -2.9 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -11.9 | |||||
3-Year EBITDA Growth Rate | 44.5 | |||||
3-Year EPS without NRI Growth Rate | 36.3 | |||||
3-Year FCF Growth Rate | 31 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 53.3 | |||||
9-Day RSI | 56.47 | |||||
14-Day RSI | 57.81 | |||||
3-1 Month Momentum % | 2.75 | |||||
6-1 Month Momentum % | 7.69 | |||||
12-1 Month Momentum % | 44.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.15 | |||||
Quick Ratio | 2.04 | |||||
Cash Ratio | 1.87 | |||||
Days Inventory | 375.8 | |||||
Days Sales Outstanding | 38.54 | |||||
Days Payable | 81.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.3 | |||||
Shareholder Yield % | -0.46 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 69.97 | |||||
Operating Margin % | 25.91 | |||||
Net Margin % | 20.07 | |||||
EBITDA Margin % | 29.23 | |||||
FCF Margin % | 17.02 | |||||
OCF Margin % | 19.76 | |||||
ROE % | 29.1 | |||||
ROA % | 18.28 | |||||
ROIC % | 57.76 | |||||
3-Year ROIIC % | 284.51 | |||||
ROC (Joel Greenblatt) % | 96.98 | |||||
ROCE % | 35.25 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 13.17 | |||||
Forward PE Ratio | 12.15 | |||||
PE Ratio without NRI | 13.17 | |||||
Price-to-Owner-Earnings | 18.81 | |||||
PS Ratio | 2.53 | |||||
PB Ratio | 2.84 | |||||
Price-to-Tangible-Book | 2.86 | |||||
Price-to-Free-Cash-Flow | 15.39 | |||||
Price-to-Operating-Cash-Flow | 13.09 | |||||
EV-to-EBIT | 7.13 | |||||
EV-to-EBITDA | 6.64 | |||||
EV-to-Revenue | 1.94 | |||||
EV-to-Forward-Revenue | 1.89 | |||||
EV-to-FCF | 11.41 | |||||
Price-to-GF-Value | 1.12 | |||||
Price-to-Median-PS-Value | 1.26 | |||||
Price-to-Graham-Number | 1.29 | |||||
| Price-to-Net-Current-Asset-Value | 3.7 | |||||
| Price-to-Net-Cash | 11.85 | |||||
Earnings Yield (Greenblatt) % | 14.03 | |||||
FCF Yield % | 6.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:PLX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Protalix BioTherapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 76.381 | ||
| EPS (TTM) ($) | 0.18 | ||
| Beta | 0.0418 | ||
| 3-Year Sharpe Ratio | 0.36 | ||
| 3-Year Sortino Ratio | 0.56 | ||
| Volatility % | 68.91 | ||
| 14-Day RSI | 57.81 | ||
| 14-Day ATR ($) | 0.088973 | ||
| 20-Day SMA ($) | 2.3525 | ||
| 12-1 Month Momentum % | 44.52 | ||
| 52-Week Range ($) | 1.4104 - 3.19 | ||
| Shares Outstanding (Mil) | 80.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Protalix BioTherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Protalix BioTherapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 08:00 | In 111 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 110 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 08:30 | In 20 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 19 days | ||
| General meeting for 2026 | 2026-06-25 08:00 | 2.24 (+2.28%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 08:00 | 1.91 (-2.55%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 1.91 (-2.55%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-18 08:00 | 2.79 (-2.45%) | ||
| Annual report for 2025 | 2026-03-18 | 2.79 (-2.45%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-18 | 2.79 (-2.45%) |
Show
Entries
Protalix BioTherapeutics Inc Frequently Asked Questions
What is Protalix BioTherapeutics Inc(PLX)'s stock price today?
The current price of PLX is $2.37. The 52 week high of PLX is $3.19 and 52 week low is $1.41.
When is next earnings date of Protalix BioTherapeutics Inc(PLX)?
The next earnings date of Protalix BioTherapeutics Inc(PLX) is 2026-08-14 Est..
Does Protalix BioTherapeutics Inc(PLX) pay dividends? If so, how much?
Protalix BioTherapeutics Inc(PLX) does not pay dividend.
Guru Commentaries on AMEX:PLX
No articles.
Press Release
Articles on Protalix BioTherapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers